logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Covid-19 has delayed cancer clinical trial programs

 

Source: www.redaccionmedica.com

María Blasco recalls that investment in science “is not even at the levels prior to 2010”
Scientists gathered at the meeting ‘A new era for cancer research: towards the involvement of the whole society’, organized by the National Center for Cancer Research (CNIO), have asked to increase resources for cancer research and streamline processes so that the results of the investigations reach the patient sooner.

“Investment in science, although it has increased timidly in the last budgets, is not even at the levels prior to 2010, before the economic crisis began to be felt. The cuts in science have destroyed a lot of science and a lot of capacity to attract talent “, stated at the meeting the director of the CNIO and head of the Telomeres and Telomerase Group of the Center, Maria Blasco.

Likewise, the head of the H12O-CNIO Lung Cancer Clinical Research Unit and head of the Medical Oncology Service of the 12 de Octubre University Hospital, Luis Paz-Ares, has indicated that society has to rise up against this situation, warning of that you have to be vigilant with the promises that are made from politics.

“We invest very little in cancer research compared to neighboring countries, less than half that of France and less than a third of Germany. Cancer is a first-rate public health problem that affects many families ”, the oncologist added.

The other outstanding aspect during the meeting was the need to “accelerate the processes”. Thus, in Blasco’s view, it is “essential” that not so much time passes between the basic discovery and the drug. “This is our most immediate challenge because research is always ahead of treatments,” he highlighted.

In addition, with the Covid-19 pandemic, the situation has worsened, since, as detailed by Paz-Ares, clinical trial programs have been delayed and cancer diagnoses have been reduced by half in many countries. In this sense, the director of the CNIO has highlighted “the fragility of human civilization.”

The importance of influencing metastasis

Likewise, Blasco recalled the importance of influencing research on metastasis and the need to speed up the transfer of the results of basic research to clinical results and, therefore, to patients.

On the other hand, Francis Mojica, professor of the Department of Physiology, Genetics and Microbiology of the University of Alicante, considered the father of the Crispr gene editing technique, has given the keynote ‘Solving enigmas, fighting ailments, delighting us with Crispr ‘.

Specifically, the expert has exposed how gene editing can help treat cancer in different ways. “One of them, extremely useful, is the identification of therapeutic targets. One of the advantages of Crispr is that it allows you to screen the entire genome. There are 20,000 genes that code for proteins. Studies are done in which all the genes in that genome are modified to see what happens and thus find out which genes are related, for example, with the development of leukemia or with 30 different types of cancer. And we can also see what is the effect of eliminating the function of these genes, “he argued.

Being a genetic disease, cancer is one of the diseases whose study benefits the most from this technology. “Its continuous improvements will ensure increasingly sophisticated cancer research, and open the way to future precision medicine therapies that specifically target tumor cells,” said the professor.

Another utility of Crispr is that it makes it possible to generate experimental models, animal models. “Cells modified with Crispr are implanted in worms or mice, to see the evolution of a cancer and look for its weak points,” Mojica explained, to add that Crispr has managed to cure a tumor by injecting it with the tools of these techniques. “With a variant called Crispra, the expression of several genes is activated to eliminate a tumor,” Mojica added.

During his lecture he also explained how these tools facilitate the study of living beings in a way unthinkable in the pre-Crispr era, also making it possible to answer questions and solve previously unapproachable problems.

The many applications of Crispr

Regarding the applications of Crispr, Professor Mojica has also addressed its use, for example, in plants to, among other things, increase their ability to improve anticancer drugs produced with them or to avoid the use of components toxic in them that may be related to the acquisition of cancer.

“Now in Spain the five-year survival of a patient diagnosed with cancer exceeds 55%”
These prevention-focused techniques are also useful, for example, getting some plants to have a very low level of nicotine. In any case, according to Mojica, the Crispr technique is “improvable”. “There is still a lot of room to improve the efficiency and robustness of these systems and, consequently, their safety”, he asserted.

At a meeting, the president of the Rosae Association of breast cancer patients, María Luisa Villafranca, summarized the importance of this issue in the phrase: “Research is life.” “Since I was diagnosed with breast cancer 20 years ago until now, the treatments have evolved a lot, now they are more personalized, adapted to each tumor. And this progress must continue to be supported. It should not be necessary for a global pandemic to arrive for us to realize how important research is, ”she detailed.

And, precisely on this advance, Luis Paz-Ares wanted to highlight a fact that illustrates what the work that these scientists do contributes. “The five-year survival of a patient diagnosed with cancer was a few years ago in the 30 percent range. Now, in our country, it exceeds 55 percent. And this is thanks to many advances and the ability to translate them into diagnostic methods ”, he has settled.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.